Related Experiment Videos
Pituitary hormones and ergot alkaloids.
Pharmacology
|January 1, 1978
Summary
Ergot drugs effectively treat hyperprolactinemia and hypersecretion of growth hormone (GH), ACTH, and MSH. These compounds disrupt prolactin secretion and inhibit GH, ACTH, and MSH from abnormal pituitary glands.
Area of Science:
- Endocrinology
- Neuroendocrinology
- Pharmacology
Background:
- Pituitary hormone secretion is regulated by complex neuroendocrine mechanisms.
- Hypersecretory pituitary states, such as hyperprolactinemia and acromegaly, require effective pharmacological interventions.
Purpose of the Study:
- To evaluate the utility of ergot drugs in studying neuroendocrine control of pituitary hormone secretion.
- To assess the efficacy of ergot drugs as a treatment for various hypersecretory pituitary conditions.
Main Methods:
- Review of existing data on the effects of ergot drugs on pituitary hormone secretion.
- Analysis of the impact of ergot drugs on normal and tumoral pituitary glands.
Main Results:
- Ergot drugs disrupt prolactin (PRL) secretion from normal and tumoral pituitary glands.
- These drugs inhibit growth hormone (GH), and potentially ACTH and MSH, secretion from hyperplastic or tumoral glands.
- Ergolines demonstrate significant PRL-lowering effects and suppress GH secretion in acromegaly.
Conclusions:
- Ergot drugs are valuable tools for neuroendocrine research and effective treatments for hyperprolactinemic states and hypersecretion of GH, ACTH, and MSH.
- Further research is needed to elucidate the precise mechanisms and sites of action for some ergot compounds.